BLTE Belite Bio, Inc.

NASDAQ
$157.72

Belite Bio, Inc. (BLTE) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.86 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +0.3% since its last earnings release on November 12, 2026.

Belite Bio Beat Consensus Estimates
Thursday, November 12, 2026 · 6:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 9:45 PM ET
Earnings Whisper
-
vs ($0.86)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $166.17

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Belite Bio, Inc.

Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases. Belite Bio Inc. is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.